Introduction {#Sec1}
============

In 1928, the discovery of penicillin by Alexander Fleming revolutionized the treatment of infectious diseases. Thereafter, development of diverse antibiotic classes led to remarkable reduction of morbidity and mortality caused by infections in surgical, transplant, cancer, and critical care patients. Most of antibiotic classes were discovered between 1940 and 1960 years known as the antibiotic golden age (Lewis [@CR63]). However, emergence of antibiotic-resistant infections limited the effectiveness of conventional therapeutic agents (Sievert et al. [@CR110]).

Based on recent reports, up to 2 million people every year are infected by resistant infections with minimum of 23,000 and 33,000 deaths per year in the USA and European Union, respectively (Cassini et al. [@CR21]., El Chakhtoura et al. [@CR31]). In this respect, it is estimated that near to 10 million deaths will be occurred by multi drug-resistant bacteria by 2050 year (Sierra et al. [@CR109]).

Accordingly, the World Health Organization (WHO) and the Infectious Disease Society of America (IDSA) have introduced antimicrobial resistance as one of the three greatest crises to public health (World Health Organization [@CR121]) (Infectious Diseases Society of America (IDSA) [@CR45]).

Antimicrobial resistance today has spread to the last line antibiotics such Vancomycin and Colistin (Kumar [@CR57]).

Since antibiotic resistance mechanisms are complicated and production of new antibiotics is time consuming and expensive, development of alternative therapeutic approaches for tackling antimicrobial resistance seems to be essential (Davies and Davies [@CR25]) (Pehrsson et al. [@CR82]).

Although development of new therapeutic approaches such as vaccines, genome editing techniques, antibodies, antimicrobial peptides, small RNAs, and phage therapy have made notable advances in the control of infectious diseases, they are still the third cause of death in the world (Trevisan et al. [@CR115]). This review focuses on recent advances in evolution of novel therapeutic agents against drug-resistant infections.

Vaccine therapy {#Sec2}
===============

Vaccines are biological agents which activate acquired immunity towards infections in a manner similar to pathogens.

The first vaccine was developed almost 200 years ago when Edward Jenner employed cowpox virus to immunize individuals towards smallpox (Riedel [@CR97]). However, the new era in development of vaccine began when Louis Pasteur established the principle of purification and injection of microorganisms to the host to induce immune responses (Kallerup and Foged [@CR51]). During the last century, notable successes were achieved in the field of vaccine development; for instance, the smallpox and rinderpest were eradicated and measles, polio, and tetanus diseases were controlled effectively through vaccination (Greenwood [@CR37]).

Mostly, vaccines are produced from the inactivated or attenuated pathogens, cell surface proteins, or toxin. Bacterial vaccines are commonly created as killed pathogen, while viral vaccines are generated as inactivated viruses. Until now, numerous vaccines have been approved to control viral and bacterial illnesses (Table [1](#Tab1){ref-type="table"}). The common features of all vaccines are specificity, safety, and long-term immunity against pathogen without unwanted immune responses such as hypersensitivity and autoimmunity in host (Vartak and Sucheck [@CR116]). In this respect, different generations of vaccines have been developed to control infectious diseases, including killed and live attenuated vaccines as the first generation, toxoid and subunit vaccines as the second generation, and recombinant and DNA vaccines as third generation vaccines (Pöri and Pinja [@CR85]) (Fig. [1](#Fig1){ref-type="fig"}).Table 1List of approved vaccines by 2018 (<http://www.immunize.org/timeline/>)Approved vaccine listYearEventsInfluenza vaccinesa. Afluriab. FluMistc. Fluarix Quadrivalentd. Fluade. Rapivabf. FluzoneSeptember 28, 2007FDA approved Afluria, a new inactivated influenza vaccine for use in people age 18 years and older.September 19, 2007FDA approved use of FluMist nasal-spray influenza vaccine in children age 2--5 years.January 11, 2018FDA approved expanded pediatric age indication for Fluarix Quadrivalent influenza vaccine.November 24, 2015FDA approved new injectable influenza vaccine, Fluad, for use in people age 65 years and olderDecember 19, 2014FDA approved Rapivab to treat influenza infection.December 11, 2014FDA approved quadrivalent formulation of Fluzone Intradermal inactivated influenza vaccine.Hib vaccines (*Haemophilus influenzae* type b)a. ActHIB ® (Sanofi Pasteur)b. Pedvax HIB ® (Merck)c. Hiberix® (GSK)March 1993Conjugated *Haemophilus influenzae* type b vaccines (ActHIB by Connaught/Mérieux and OmniHib by SmithKline Beecham) were licensed.Dec 20, 1989Conjugated *Haemophilus influenzae* type b (Hib) vaccine (PedvaxHIB by Merck) was licensed.January 14, 2016FDA approved Hiberix for full Hib vaccine series.DTaP Vaccines (Diphtheria, Tetanus, acellular Pertussis)a. Daptacel ® (Sanofi Pasteur)b. Infanrix ® (GSK)Jan 29, 1997Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Infanrix by SmithKline Beecham) was licensed for the first four doses of the series.May 14, 2002Diphtheria and tetanus toxoids and acellular pertussis vaccine (Daptacel by Aventis Pasteur) was licensed.Hepatitis B Vaccinesa. Engerix B ® (GSK)b. Recombivax ® (Merck)c. DynavaxJuly 23, 1986Recombinant hepatitis B vaccine (Recombivax HB by Merck) was licensed.Aug 28, 1989Recombinant hepatitis B vaccine (Engerix B by SmithKline Beecham) was licensed.November 9, 2017FDA licensed Heplisav-B, the new hepatitis B vaccine from Dynavax, for use in adults age 18 and older.Hepatitis A Vaccinesa. Vaqta ® (Merck)b. Havrix ® (GSK)c. TwinrixFeb 22, 1995The first inactivated hepatitis A vaccine (Havrix by SmithKline Beecham) was licensed.Mar 29, 1996A second inactivated hepatitis A vaccine (Vaqta by Merck) was licensed.May 11, 2001A combined hepatitis A inactivated and hepatitis B (recombinant) vaccine (Twinrix by SmithKline Beecham) was licensed.Polio Vaccinea. IPOL ® (Sanofi Pasteur)June 25, 1963Trivalent oral polio vaccine was licensed.Dec 21, 1990An enhanced-potency inactivated poliovirus vaccine (Ipol by Pasteur Méérieux Vaccins et Serums) was licensed.Yellow fever vaccinea. YF-VaxJan 3, 1978Yellow fever vaccine (YF-Vax by Connaught) was licensed in the USA.May 22, 1953Yellow fever vaccine (Merrell National Labs) was first licensed in the USA.HPV vaccines (*Human Papillomavirus*)a. Gardasil-9® (Merck)June 8, 2006FDA licensed the first vaccine developed to prevent cervical cancer (Gardasil by Merck & Co., Inc.), precancerous genital lesions, and genital warts due to *human papillomavirus* (HPV) types 6, 11, 16, and 18.Pneumococcal Vaccinesa. Prevnar 13 ® (Wyeth)b. Pneumovax 23 (Merck)July 1983Two enhanced pneumococcal polysaccharide vaccines were licensed (Pneumovax 23 by Merck on July 11 and Pnu-Imune 23 by Lederle on July 21). These vaccines included 23 purified capsular polysaccharide antigens of *Streptococcus pneumoniae* and replaced the 14-valent polysaccharide vaccine licensed in 1977.February 24, 2010FDA approved licensure of Pneumococcal 13-valent conjugate vaccine (PCV13), which offers broader protections against *Steptococcus pneumoniae* infections.February 24, 2010FDA approved pneumococcal 13-valent conjugate vaccine (Prevnar 13), which offers broader protection against *Streptococcus pneumoniae*.Meningococcal conjugate vaccinesa. Menactra ® (Sanofi Pasteur)b. Menveo ® (Novartis)January 23, 2015FDA approved the use of Bexsero, the second vaccine licensed in the USA to prevent serogroup B meningococcal disease.April 22, 2011FDA approved the first vaccine (Menactra, meningococcal conjugate vaccine, sanofi pasteur) to prevent meningococcal disease in infants and toddlersFebruary 19, 2010FDA approved licensure of Menveo (Novartis), meningococcal conjugate vaccine for people ages 11 through 55 years.Tdap vaccines (Tetanus Toxoid, Reduced Diphtheria toxoid and acellular pertussis---adolescent formulation)a. Boostrix ® (GSK)b. Adacel ® (Sanofi Pasteur)July 8, 2011FDA approved Boostrix (Tdap, GlaxoSmithKline) to prevent tetanus, diphtheria, and pertussis in older people.June 10, 2005FDA licensed a 2nd Tdap vaccine (Adacel by sanofi pasteur) for use in persons ages 11--64 years.Varicella Vaccinea. Varivax ® (Merck)Mar 17, 1995Varicella virus vaccine, live (Varivax by Merck) was licensed for the active immunization of persons 12 months of age and older.Combination Vaccinesa. Kinrix ® (GSK)b. Pediarix ® (GSK)c. ProQuad ® (Merck)d. Quadracel® (Sanofi Pasteur)June 24, 2008FDA approved new DTaP-IPV vaccine (Kinrix) for use in children ages 4--6 years.Dec 13, 2002A vaccine that combined the diphtheria, tetanus, acellular pertussis, inactivated polio, and hepatitis B antigens (Pediarix by GlaxoSmithKline) was licensed.Sept 6, 2005A vaccine that combined the measles, mumps, rubella, and varicella antigens (Proquad by Merck) was licensed. The vaccine was indicated for use in children 12 months to 12 years.March 24, 2015FDA approved Quadracel, a new combination DTaP+IPV vaccine for use in children age 4--6 years.Fig. 1Several generations of vaccines have been developed to control infectious diseases through inducing immune responses in the host

Live attenuated vaccines {#Sec3}
------------------------

As noted above, the attenuated vaccines are viral particles or live bacterial cells with decreased virulence capable to induce immune responses in the host (Clem [@CR23]). There are various approaches to introduce attenuating mutations in pathogens such as serial culture under suboptimal conditions (i.e., low temperature) or non-human hosts (i.e., animal embryo). Hence, based on the host type, the attenuated vaccines created as nerve tissue vaccines, embryonated egg vaccines, and cell culture vaccines. An attenuated vaccine as mimicking the wild-type pathogen can induce a comprehensive immune response including both cellular and humoral immunity with long lived protection (Mak and Saunders [@CR66]).

The smallpox vaccine derived from cowpox was the first viral attenuated vaccine which was developed by Edward Jenner in 1796 (Riedel [@CR97]).

At present, numerous attenuated vaccines have been approved for clinical use. Bacillus Calmette Guérin (BCG) vaccine against tuberculosis (TB), MMR vaccine with trade name Priorix ® (including three attenuated viruses measles, mumps, and rubella), FluMist ® Quadrivalent against Influenza virus and Zostavax ® (Merck & Co.) towards Herpes Zoster virus (Med Immune, LLC) are examples of successful attenuated live vaccines under clinical use (Ravanfar et al. [@CR95]) (Kallerup and Foged [@CR51]).

However, there are some limitations to employ the attenuated vaccines in patients with immune system disorders or with history of organ transplant (Vartak and Sucheck [@CR116]). Therefore, the modified versions of attenuated vaccines such as killed, subunit, or peptide vaccines have been developed to prevent infection.

Inactivated vaccines {#Sec4}
--------------------

Inactivated vaccines are the killed version of pathogens resulting from pathogens inactivation by physical (heat) or chemical (formaldehyde) agents so that pathogen can induce immune responses without replication in the host. Although the immunogenicity of inactivated vaccines is lower due to conformational changes of antigens inducing immune responses (Pöri and Pinja [@CR85]), they are extremely safe due to losing the replication ability (Kallerup and Foged [@CR51]). Until now, several inactivated vaccines have been developed and licensed such as Typhoid vaccine, AGRIFLU ® as a trivalent vaccine against influenza type A and B viruses, Havrix ® (GSK) to prevent Hepatitis A disease and IPOL ® (Sanofi Pasteur) that targets Poliovirus (Pöri and Pinja [@CR85]).

Toxoids {#Sec5}
-------

Some bacteria are not directly pathogenic but infection is caused by secretory toxins. For example, tetanus disease is caused by a neurotoxin called Tetanospasmin produced by *Clostridium tetani*. In such cases, protective immune response is created by toxoid vaccines resulting from detoxification of secretory toxin by heat or formalin treatments.

Examples of toxoid vaccines are including vaccines developed against diphtheria, tetanus, and pertussis toxins. For instance, DTaP Vaccine is a combined vaccine for protection of children against diphtheria and tetanus and pertussis diseases. A new version of this vaccine called Tdap is also developed for protection of adults against the noted diseases (Yih et al. [@CR125]).

Totally, high safety and stability as well as transmission inability to non-immunized persons are the major properties of toxoid vaccines. However, one of the major drawbacks of vaccination with toxoids is the requisite of more than one dose of vaccine to provoke protective immunity, a phenomenon necessitating the presence of adjuvant with toxoid (Baxter [@CR9]).

Recombinant protein vaccines {#Sec6}
----------------------------

The production of recombinant proteins is one of the new approaches to create safe vaccines especially against nonculturable or difficult-to-culture viruses (Hudu et al. [@CR44]) (Eisenstein [@CR30]). The recombinant protein vaccines as the third-generation vaccines can induce both humoral (antibody) and cellular immune responses in the host (Fig. [1](#Fig1){ref-type="fig"}). In this type of vaccines, genes encoding protective antigens are recombinantly expressed (Baxter [@CR9]) (Scott and Cheryl [@CR105]).

In 1987, Hilleman M et al. developed Recombivax as the first recombinant vaccine against hepatitis B through cloning and recombinant expression of the hepatitis B surface antigen in *Saccharomyces cerevisiae* (Hilleman [@CR42]). Until now, numerous recombinant vaccines have been approved against viral pathogens such Human papilloma virus (Slade et al. [@CR111]), Influenza (Girard et al. [@CR35]), and bacterial pathogens including Bacillus Calmette-Guerin (BCG) (Jacobs et al. [@CR48]) and Meningococcal (Cooper et al. [@CR24]).

Recently, a recombinant vaccine called shingrix has been developed against shingles disease caused by the varicella zoster virus with a high level protection (up to 90%) against this disease (Raedler [@CR90]). One of the main challenges in the development of recombinant vaccines is the selection of the suitable target antigens. At present, reverse vaccinology is one of the promising approaches to identify repertoire of antigens that are highly antigenic, with surface *exposure*, and conserved among multiple strains (Rappuoli et al. [@CR94]) (Zeng et al. [@CR129]).

DNA vaccines {#Sec7}
------------

In DNA vaccines, immune response is induced through plasmid DNA encoding interested antigen (Fig. [1](#Fig1){ref-type="fig"}). Owing to safety and simplicity, DNA vaccines have several advantages over conventional vaccines especially in compare to attenuated and killed vaccines. After transfection of plasmid DNA, target antigen is expressed inside cells and induces immune responses of the host (Hudu et al. [@CR44]). Although DNA vaccines have several benefits including high stability, cost affectivity and the ability to induce both humoral and cellular immune responses, some limitations still exist regarding the use of these vaccines (Okuda et al. [@CR77]). For instance, due to the low extent of antigens produced in the body, Th2-type immune responses is weakly induced in DNA vaccines (Shi et al. [@CR107]). At present, researchers using techniques such as in vivo electroporation have improved the efficacy of these vaccines.

Until now, several DNA vaccines have been developed some of which are under clinical studies but none of them approved yet (Bar-Or et al. [@CR7]) (Papadopoulou et al. [@CR80]). For instance, Bar-Or et al. used DNA encoding myelin protein as vaccine for immunotherapy of multiple sclerosis (MS). The results indicated a notable reduction in levels of myelin-specific autoantibodies (Bar-Or et al. [@CR7]) (Papadopoulou et al. [@CR80]). In another study, a DNA plasmid encoding Aβ42 protein was developed as DNA vaccine against Alzheimer disease (Lambracht-Washington and Rosenberg [@CR59]). Recently, researchers have developed a DNA vaccine with ability to induce immune responses in immunized mice against *Acinetobacter (A.) baumannii* through importing *Acinetobacter* NlpA gene into pEGFP-C2 vector (Hashemzehi et al. [@CR40]). Also, a DNA vaccine has developed against *Vibrio (V.) anguillarum* through construction of OmpK gene as immunogenic protein of *V. anguillarum* in pcDNA3.1 vector that can induce humoral and cellular immune responses in immunized fish with vector expressing OmpK gene (Xu et al. [@CR122]).

Unlike, other vaccines such as recombinant protein vaccines and live attenuated virus which their generation is prolonged and costly, DNA vaccines are flexible and produced quickly. However, there are some limitations in the use of DNA vaccines such as inducing weak immune response, the probability of activation of oncogenes during genomic integration of DNA vaccines, as well as production of anti-DNA antibodies in the body (Harrison and Bianco [@CR39]). Because of these limitations, no DNA vaccines have been FDA approved to combat infections.

Subunit vaccines {#Sec8}
----------------

Subunit vaccines are produced through purification of antigens directly from the pathogen. So that, based on the type of antigen (surface molecules, subcellular, and toxins) used in subunit vaccine, the type of immune responses in the host is different (Baxter [@CR9]) (Scott and Cheryl [@CR105]). Polysaccharide antigens induce T-independent immune response whereas protein antigens induce T cell-dependent responses. Conjugated vaccines are another type of subunit vaccines in which a protein carrier is used to deliver the polysaccharide antigen. In this type of vaccine, polysaccharide with poorly immunogenic property is conjugated to a protein carrier which is strongly immunogenic.

In the conjugated vaccines, both T-dependent and T-independent immune responses are activated in the host. Totally, Diphtheria Toxoid D (Pace and Pollard [@CR79]), CRM197 (Shinefield [@CR108]), Protein D (Plosker [@CR84]), or Outer Membrane Protein Complex (OMPC) (Lenoir et al. [@CR62]) are the most common carriers used in conjugated vaccines. At present, several conjugated vaccines have been approved to control infections; for instance, PedvaxHIB is a conjugated vaccine in which capsular polysaccharide of *Haemophilus influenzae* type b has been conjugated to outer membrane protein of *Neisseria (N.) meningitidis* group B (Ahonkhai et al. [@CR2]). Pneumococcal 13-valent conjugate vaccine with trade name Prevnar 13 is composed of diphtheria CRM197 protein as carrier and seven serotypes of *Streptococcus (S.) pneumoniae* (4, 18C, 6B, 19F, 9V, 14 and 23F).

Pentacel as a pentavalent vaccine conjugated to Tetanus toxoid is made for simultaneous protection against pertussis, tetanus, diphtheria, *Haemophilus influenzae* type b, and polio diseases (Sucher et al. [@CR113]). Menveo conjugated vaccine composed of diphtheria CRM197 oligosaccharide and has been developed for immunization against four serogroups *of N. meningitidis* bacteria (A, C, Y, and W-135) causing invasive meningococcal disease (Deeks [@CR26]). Recently, a Modified Vaccinia Ankara (MVA) expressing the ZIKV protein NS1 (ZIKV-NS1) has been developed with ability of inducing robust humoral and cellular responses in adult mice (Brault et al. [@CR17]).

Antibody therapy against infectious diseases {#Sec9}
============================================

Despite considered advantages of vaccines for prophylaxy of infectious diseases, there are some limitations regarding induction of immune responses, especially in immunosuppressed individuals such as diabetics, bone marrow suppressed and HIV patients. In this respect, antibody therapy can be an attractive approach for providing temporary protection against a microbial agent. Commonly, antibody therapy is faster than vaccines in emergency situations (Graham and Ambrosino [@CR36]). Until now, several antibodies have been approved to treat a number of diseases such as some types of cancer and autoimmune disorders (Eyvazi et al. [@CR32]).

Previous studies for control of *A. baumannii* infections by immunization indicated that, use of immune serum as passive immunization and or *A. baumannii* bacteria as active immunization both have protective effect on mice suffering from pneumonia or lethal bacteremia infections (McConnell et al. [@CR70]., McConnell and Jerónimo [@CR69]) (Huang et al. [@CR43]).

In the 1890s, for the first time, antibodies were extracted from immunized animal's serum and introduced as therapeutic agents to bacterial infections. Emil von Behring first indicated that serum of rabbit immunized with tetanus toxin can control tetanus infection in the rabbits (Winau and Winau [@CR120]) (Casadevall and Scharff [@CR20]). Afterwards, Emil von Behring received Nobel Prize in 1901 due to development of serum therapy to diphtheria (Winau and Winau [@CR120]). Until the early twentieth century, serum therapy was a successful treatment against most of viral infections such as influenza, measles (Janeway [@CR49]), and polio (Hammon et al. [@CR38]) and bacterial infections including *Haemophilus influenza* B, meningococcus, and pneumococcus (Alexander et al. [@CR3]) (Casadevall and Scharff [@CR20]). However, when antibiotics as therapeutics agents of bacterial infections were discovered, the application of serum therapy was reduced. With development of hybridoma technology by Milstein and Köhler in 1975 regarding generation of murine monoclonal antibodies through immortalizing B cells known as hybridomas, a new era was began in the treatment of different diseases using monoclonal antibodies and passive immunization (Köhler and Milstein [@CR54]).

Although hybridoma technology have made a notable contribution in the discovery of antibodies but animal-based approaches displayed some limitations especially for toxic and hapten targets. To eliminate these limitations, researchers have developed new non-animal-based strategies to develop monoclonal antibodies such as phage display libraries.

At present, two main strategies for developing mAbs are used including animal immunization and surface display methodologies such phage display technology (McCafferty et al. [@CR67]) (Rahbarnia et al. [@CR93]).

Antibody phage display technology is an in vitro screening process independent from any immune system in which the antibody fragments are displayed in phages surface (Rahbarnia et al. [@CR92]). For instance, human scFv phage library with high diversity of gene repertoires provides a rich source of scFvs to almost any antigen (Rahbarnia et al. [@CR93]).

Until now, several mAbs have been approved to combat infectious disease. For instance, Raxibacumab (ABthrax®) as the first antitoxin antibody is a human IgG1 produced by phage display technology against *Bacillus (B.) anthracis* protective antigen which has been approved in 2012 to prevent inhalation anthrax (Migone et al. [@CR71]). Bezlotoxumab is another example of human monoclonal antibody approved in 2017 that has been developed to prevent *Clostridium difficile* infection through targeting toxin B (Navalkele and Chopra [@CR75]). Finally, Obiltoxaximab (Anthim®) is a Chimeric (mouse/human) IgG1/κ antibody approved in 2016 which was produced as a preventive agent against *B. anthracis*. This antibody targets protective antigen (PA) component of *B. anthracis* toxin (Capela et al. [@CR19]).

Currently, monoclonal antibodies are used for treatment of several diseases including cancer, Crohn's disease, rheumatoid arthritis, ulcerative colitis, and multiple sclerosis. However, antibody therapy of infectious diseases is limited due to the need for high doses of antibodies and cost of manufacturing (Patel et al. [@CR81]). So that, studies regarding application of monoclonal antibodies have only been focused on bacteria that cause toxin-mediated infection (e.g., Anthrax, *Clostridium (C.) difficile colitis*), and viral diseases such Ebola, HIV, MERS, and SARS which had no available vaccines (Graham and Ambrosino [@CR36]).

Therefore, the alternative therapeutic approaches such as vaccines and antimicrobials have priority over infection prevention and control.

Recently, researchers have developed a novel technology known as DNA-encoded monoclonal antibodies (DMAbs) to target Zaire Ebola virus that unlike the conversional antibodies provide a long-term protection against Ebola virus. It is now under preclinical trials (Patel et al. [@CR81]).

Antimicrobial peptides {#Sec10}
======================

Antimicrobial peptides (AMPs) or host defense peptides (HDPs) are conserved molecules that act as one of the host defense mechanisms to combat infections (Yeaman and Yount [@CR124]). AMPs exhibit in living organisms from prokaryotes to humans. At present, AMPs are considered as promising therapeutic candidates due to their key role in the regulation of arteriogenesis, inflammatory responses, angiogenesis, wound healing responses, and cell signaling pathways (Zaiou [@CR126]) (Baba et al. [@CR6]., Kim et al. [@CR53]).

In 1939, Gramicidin as the first natural AMPs was identified from *Bacillus brevis* with antimicrobial activity against gram positive bacteria. Further studies confirmed its antimicrobial activity regarding guinea pig wound infections as alternative to antibiotics (Dubos [@CR28]). After that, several host defense peptides (HDPs) were identified in living organisms such *Hyalophora cecropia* (cecropins), *Xenopus laevis* (magainins) (Steiner et al. [@CR112]) (Zasloff et al. [@CR128]). Generally, the unique structural properties of AMPs distinct them from other molecules; for instance, the net positive charge of AMPs facilitates electrostatic interactions with anionic lipopolysaccharides or lipoteichoicacids of microbial membranes (Jenssen et al. [@CR50]; Yeaman and Yount [@CR124]). Also, due to hydrophobicity characteristic, AMPs can penetrate into the host cells to lyse membrane (Aoki and Ueda [@CR5]).

It should be also noted that the antibacterial potency of AMPs is strongly dependent on their secondary structure; for instance, α-helical content in linear AMPs affects their antimicrobial activity (Jenssen et al. [@CR50]).

Until now, more than 1500 AMPs have been isolated from several organisms including fungi, plants, bacteria, and animals (Naafs [@CR74]). But only a limited number AMPs are approved for clinical use due to proteolytic degradation and low stability in the body.

Cyclic AMPs were the first AMPs offered for clinical use including Polymyxins, Gramicidin, Tyrothricin (tyrocidin is the main component), Bacitracin, and Daptomycin (Molchanova et al. [@CR73]). In this respect, Polymyxins are considered as last line therapy for multidrug-resistant infections caused by Gram-negative bacteria which first isolated from *Paenibacillus polymyxa* strains. However neuro- and nephrotoxicity problems have limited Polymyxins application (Lenhard et al. [@CR61]). At present, researchers have generated several analogs of Polymyxins with low toxicity such as CB-182,804, Pfzer 5X, Monash FADDI, Queensland, Northern antibiotics (Rabanal and Cajal [@CR89]) but neither of them have been approved (Lenhard et al. [@CR61]).

For instance, Daptomycin (Cubicin®) was approved in 2003 for the treatment of skin and bloodstream infections caused by susceptible and methicillin-resistant strains of *Staphylococcus aureus* (Afacan et al. [@CR1]). After that, Surotomycin (CB-315, CB-183315, and MK4261) as one of daptomycin analogs was developed to treat *C. difficile*-associated diarrhea, but recently, it was failed due to lack of superiority over standard of treatment (Boix et al. [@CR15]) (Petrosillo et al. [@CR83]). Murepavadin (POL 7080) as cyclic synthetic peptide (14aa) is known as an attractive drug to treat ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) caused by *Pseudomonas*. It functions through interaction with lipopolysaccharide transport protein D (LptD) and blocks export mechanism of LPS in the outer membrane and kill the bacterium. The phase 2 clinical trials of this peptide has been completed regarding noncystic fibrosis bronchiectasis (Butler et al. [@CR18]). Recently, the phase III trials of murepavadin to treat nosocomial pneumonia have been stopped due to occurrence of *higher than estimated* of acute kidney injury in patients treated with murepavadin) <https://www.polyphor.com/news/corporate-news-details/?newsid=1775911>).

Besides cyclic analogs, today several linear AMPs have been identified that are effective towards wide range of gram-positive and gram-negative bacteria; for instance, antimicrobial characterization of pexiganan is confirmed towards Methicillin-resistant *Staphylococcus (S.) aureus*, extended spectrum beta-lactamases (ESBL) producing bacteria, vancomycin-resistant *Enterococcus* (VRE) (Afacan et al. [@CR1]) (Rabanal and Cajal [@CR88]). In addition to the noted cases, several AMPs such Omiganan (CLS001 or MBI-226) (Sierra et al. [@CR109]), SGX942 (dusquetide) (Kudrimoti et al. [@CR56]), LTX-109 (Lytixar) (Sierra et al. [@CR109]) are now under clinical studies.

Recently, a cationic peptide called as PEP-NJSM has been identified to treat *S. epidermidis* biofilm formation-related infections (Mnif et al. [@CR72]).

Although notable success has been achieved in identification of novel AMPs, but due to the proteolytic degradation and toxicity of AMPs, rarely approved by FDA. Hence, one of the major challenges of the scientists is related to increase of stability, safety, and efficiency of AMPs.

Genome editing technologies to fight infectious diseases {#Sec11}
========================================================

Newly, genome engineering using programmable nucleases has been developed to treat various types of disorders (Safari et al. [@CR103]).

So far, four types of engineered nucleases have been applied for targeted genome modification including transcription activator-like effector nucleases (TALENs), and zinc-finger nucleases (ZFNs), homing endonucleases (HEs), and clustered regularly interspaced short palindromic repeat (CRISPR-Cas9).

In the beginning, these nucleases identify target DNA sequence and break the double stranded DNA then the created gap is repaired by two distinct mechanisms comprising non-homologous end joining pathways (NHEJ) and homologous recombination (HR) (Rouet et al. [@CR101]). HR strategy is only suitable to insert a high copy number from a homologous sequence while NHEJ creates insertions or deletions (known indels) as an error-prone mechanism (Isken and Maquat [@CR46]) (Kucherlapati et al. [@CR55]).

Researchers to struggle infectious diseases through genome editing target crucial genes involved in virulence, replication, and activation of pathogen through the error-prone NHEJ mechanism. However, the utilization of the NHEJ against viruses is only limited to viruses carrying DNA, such as human immunodeficiency virus (HIV), since these programmable nucleases can cut only genomic DNA. Recently, the modified CRISPR-Cas9 system has been developed to produce gRNAs complementary to the genome of hepatitis C virus (HCV), to target RNA-based viruses (Price et al. [@CR86]).

In a recent study, the replication of HIV virus was limited considerably through a combinatorial CRISPR/Cas9 system to target several regions of the HIV genome by two strong gRNAs (Lebbink et al. [@CR60]).

The utilization of genome editing strategy in order to target virulence factors and bacterial antibiotic resistance genes back to 2004 year when Citorik et al., employed viral transduction method to transfer molecular constructs into the bacterial cells (Citorik et al. [@CR22]). In this method, M13-phagemid vector carrying CRISPR-Cas9-based RNA-guided nucleases was used for targeting the *bla*SHV-18 or *bla*NDM-1 genes, responsible for extended spectrum and pan-resistance to β-lactam antibiotics, respectively (Citorik et al. [@CR22]).

In another study, researchers examined the specificity of the CRISPR-Cas system for introduction of a single-nucleotide mutation in the gyrase gene (*gyrA*D87G) which is responsible for resistance to quinolones. Results were confirming the specificity of CRISPR-Cas system so that only *Escherichia coli* cells harboring the *gyrA*D87G mutation were killed by a phagemid vector but not *E. coli* strains carrying the wild-type gyrA gene (Citorik et al. [@CR22]).

In a study done by Bikard et al. in 2014, CRISPR-Cas system was used for targeting the methicillin resistance gene, mecA, in *S. aureus* that led to the notable reduction of methicillin resistance. Also, studies indicated that, this antimicrobial system leads to immunization of nonpathogenic *S. aureus* strains towards the transfer of antibiotic-resistant plasmids (Bikard et al. [@CR12]). After that, in vivo studies on mouse infected to *S. aureus* was confirming more effect of CRISPR-Cas9 phagemids to treat skin colonization than standard therapy with mupirocin (Bikard et al. [@CR12]).

Recently, in one study on *Enterococcus (E.) faecalis*, CRISPR-Cas genome defense system was used to block the acquisition of antibiotic resistance by horizontal transfer system in *E. faecalis* (Rodrigues et al. [@CR100]).

Although notable advances have been achieved regarding employment of genome editing strategy against infectious diseases, there are still some limitations for the use of this tool in clinical settings, such as the possibility of mutants escape or off-target mutations in the genome, so recent efforts of researchers are in order to increase specificity and sensitivity of genome editing and predicting off-target effects. However, the prediction of cleavage rate and nuclease target availability in living cells is difficult due to the complexity of chromatin structure and cell nucleus.

RNA interference-based therapeutics to combat infections {#Sec12}
========================================================

RNA interference (RNAi) technology is known as one of the promising therapeutic strategies regarding autoimmune disorders, cancer, and infectious diseases (Dyawanapelly et al. [@CR29]; Zarredar et al. [@CR127]). Generally, RNAi technology relies on the use of specific nucleic acids such as siRNAs and miRNA for knockdown or knockout expression of the genes involved in disease.

The modern era in the treatment of intracellular infections by RNAi technology was begun when McCaffrey et al. employed specific siRNAs and shRNAs to target key genes of hepatitis C virus (McCaffrey et al. [@CR68]). Afterwards, Bitko et al. achieved promising results regarding Para influenza virus control through specific siRNA design (Bitko et al. [@CR13]).

Until now, several types of nucleic acids including DNAs, siRNAs, miRNA, and shRNA have been used effectively to harness lethal intracellular infections (Blagbrough and Zara [@CR14]). MicroRNAs (miRNAs) are small non coding RNAs (\~ 22 nt) that bind to complementary sequences in the 3′-untranslated region of messenger RNA and control transcription and translation processes (Bartel [@CR8]). In comparison with siRNA, application of miRNA as therapeutic agents is limited due to low specificity and their unpredictable mechanism so that only two miRNAs have been developed as therapeutic candidate (Lam et al. [@CR58]). However, miRNAs are notable regarding mutagenic diseases such as cancer (Lam et al. [@CR58]) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2The miRNAs and siRNAs can bind to complementary sequences in mRNA and regulate the expression of gene through translational repression, degradation of mRNA. The miRNAs target mRNAs through partial complementarity while siRNA bind to mRNA as fully complementary base pairing

SiRNAs as main regulators of the post-transcriptional gene silencing pathways are more efficient than other types of nucleic acids (Pushparaj et al. [@CR87]) (Khatri et al. [@CR52]). The inhibitory effect of siRNAs was documented when Bitko and Barik harnessed growth of respiratory syncytial virus (RSV) through a synthetic siRNA blocking mRNAs coding protein F and polymerase of viral (Bitko et al. [@CR13]).

During the past decade, satisfactory outcomes have been achieved regarding RNAi-based therapy of intracellular infections such malaria, HIV/AIDS, influenza, tuberculosis, leishmaniasis, RSV, hepatitis, and other infections (Dyawanapelly et al. [@CR29]).

For instance, leishmaniasis is a parasitic disease that is presented in three forms cutaneous, mucocutaneous, and visceral leishmaniasis (VL). At present, chemotherapy is the most common therapeutic strategy against *leishmania*. However, emergence of drug-resistant parasites has limited conventional therapeutic approaches (Farajnia et al. [@CR33]) (Rahbarnia et al. [@CR91]). In this respect, researchers have examined the application of RNAi technology to harness leishmaniasis disease. For this, Robinson et al. targeted α-tubulin locus by siRNA to restrain growth of *leishmania* parasite but the results were not promising (Robinson and Beverley [@CR99]). In study undertaken by Dey et al., a specific siRNA was used to silence C--C chemokine receptor 5 (CCR5) in *leishmania* through which the parasite titer was considered declined in murine visceral leishmaniasis treated by CCR5 siRNA in the primary stage of infection (Bhattacharyya et al. [@CR11]).

Nevertheless, researches in the field of gene therapy of bacterial infections are more promising. For instance, researchers employed a siRNA (21 bp) to target coagulase activity in methicillin-resistant *S. aureus* (MRSA) strains and revealed inhibitory effect of the siRNA in MRSA coagulation under in vitro conditions. Also, inhibitory effect of the synthetized siRNA was confirmed by remarkable reduction of the bacterial titer in a murine model infected by hematogenous pulmonary infection (Yanagihara et al. [@CR123]).

One of the recent reports regarding siRNAs application is related to Nile virus (WNV) control (Beloor et al. [@CR10]). At present, there is no vaccine against this virus. During the study done by J. Beloor, a synthetic RNA called siFvEJW was designed to limit WNV through targeting a conserved sequence in E protein of the WNV. The results of in vivo studies indicated the inhibitory effect of the siRNA in mice at late stages of neuroinvasive disease (Beloor et al. [@CR10]).

Although siRNAs have been known as promising therapeutic tools, but their application has been limited due to the low stability, the possibility of immunogenicity, degradation and off-target effects (Ryther et al. [@CR102]) (Whitehead et al. [@CR119]).

One of the main challenges facing researchers is the choice of suitable cellular carriages such viral and non-viral vectors for the effective delivery of siRNAs (Thomas et al. [@CR114]) (Islam et al. [@CR47]). The most common viral vectors used are including retrovirus vectors, lentivirus, adeno-associated virus, oncoretrovirus, adenovirus, and herpes simplex virus-1-based vectors (Islam et al. [@CR47], Lambracht-Washington and Rosenberg [@CR59]., Oh and Park [@CR76]). Totally, the viral vectors have higher efficiency but immunogenicity, carcinogenicity, and inducing inflammatory responses and possibility of integration into the host genome limit their therapeutic applications. In contrast, researchers have developed non-viral vectors with higher safety, efficiency, and ability to systemic and/or local delivery of nucleic acid (Semple et al. [@CR106]) (Wang et al. [@CR117]).

Recently, RNA nanomedicine technology as one of non-viral nanovector systems has been developed for effective delivery of small RNA-based therapeutics (Riley and Vermerris [@CR98]).

The recent efforts have been focused on increase of the stability of small RNAs versus nucleases in order to improve of small RNAs effectiveness as attractive therapeutic tools.

Phage therapy {#Sec13}
=============

The history of phage therapy for control of infections go back to when antibiotics still had not been discovered. Commonly, phages can control infections through lysis of infected bacteria (Lin et al. [@CR65]). Since phages target only specific bacterial species and have no effect on the normal bacterial flora, so the possibility of secondary infections in phage therapy is lower than antibiotic therapy. Despite, many advantages of phage therapy such high specificity, low toxicity and self-amplification and anti-biofilm activity, there is no still FDA approved phage therapy as alternative to antibiotics (Donlan [@CR27]) (Bourdin et al. [@CR16]), because of phages that are usually identified and eliminated by the host immune system through generation of specific antibodies. On the other hand, intracellular infections maybe inaccessible for phage particles (Henein [@CR41]). Nevertheless, the emergence of antibiotic-resistant infections has been led to redevelopment of phage therapy as alternative to treat infections. One of the notable progresses in phage therapy is related to identification of the genes encoding lytic enzymes of phage that are expressed during lytic cycle by the bacterial host. The lytic proteins hydrolyze the cell wall of the host to excrete viral progeny. In this respect, two main classes of lytic proteins have been isolated comprising a peptidoglycan protein called lysine and a transmembrane protein known as holin which lysine protein plays the main role in the lysis of bacterial cell, so it is more notable as an antimicrobial candidate (Lin et al. [@CR65]). In a study performed on diabetic patients, phage therapy significantly reduced the foot ulcer infections caused by MDR *S. aureus* (Fish et al. [@CR34]).

Newly, researchers improved the efficiency of phage therapy to target drug-resistant bacteria through engineering phages and using of the lytic enzymes of phages (Lin et al. [@CR65]). Until now, several lytic proteins such ABgp46, PlyF307, Cpl-1, PlyCD, and PlySs2 have been purified and their antibacterial properties confirmed against various drug-resistant bacteria such as MDR *A. baumannii*, *Pseudomonas (P.) aeruginosa*, and *Salmonella (S.) typhimurium*, *S. pneumoniae*, and MRSAs (Oliveira et al. [@CR78]),(Schmelcher et al. [@CR104]). For instance, in one study, a phage cocktail was designed to treat wound infections caused by *A. baumannii* in which four *A. baumannii* lysing phages were combined to one phage inhibiting bacterial growth to target both capsulated and uncapsulated bacteria. The inhibitory effect of the cocktail phage was confirmed on murine model (Regeimbal et al. [@CR96]).

Although there are many unknown factors regarding phage therapy and phage-host interactions, however, advances in the field of phage therapy as an alternative to antibiotics are significant.

Conclusion and perspectives {#Sec14}
===========================

Despite notable advances regarding production of vaccines and new antibiotics, drug-resistant infections are still a serious threat to public health. At present, several promising therapeutic strategies have been developed against infectious diseases, each of them has own advantages and disadvantages.

For instance, today, vaccination is effective for prophylaxis of many infectious diseases but there is no effective vaccine to HIVs, TB, and several other infections. In this respect, RNAi technology is a promising strategy to struggle intracellular infections, including HIV/AIDS, hepatitis, RSV, influenza, HSV, malaria, and tuberculosis but still there are challenges regarding employment of suitable carriers such viral and non-viral vectors for the effective delivery of RNAs. In addition to RNAi technology, CRISPR has newly been implemented to target virulence factors of infectious bacteria. Despite the notable advances regarding the feasibility of harnessing CRISPR strategy for tackling infections, the improvement of CRISPR technology through production of nucleases with more cleavage efficiency and specificity is still needed. On the other hand, development of appropriate delivery systems with higher safety could improve treatment of resistant infections by CRISPR technology (Trevisan et al. [@CR115]).

In addition to the mentioned therapeutic strategies, more than 2,000 natural and synthetic AMPs have been developed as alternative to antibiotics (Wang et al. [@CR118]) but only a few AMPs has reached to the clinical use (Li et al. [@CR64]). The unknown molecular mechanisms of AMPs in the host and necessity of rational design of AMPs are two main barriers in the development of more efficient AMPs (Andersson et al. [@CR4]).

To accomplish the potential role of the abovementioned strategies against antibiotic resistance threat, efforts need to be accelerated and investments expanded at all stages of research, preclinical, and clinical developments.
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